$GLUE
Monte Rosa Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009324 Filed on May 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.387M $2.231M
YoY Change 186.28% 366.74%
% of Gross Profit
Research & Development $17.92M $9.273M
YoY Change 93.2% 143.07%
% of Gross Profit
Depreciation & Amortization $800.0K $300.0K
YoY Change 166.67% 322.54%
% of Gross Profit
Operating Expenses $24.30M $11.50M
YoY Change 111.25% 167.97%
Operating Profit -$24.30M -$11.50M
YoY Change 111.25%
Interest Expense $149.0K $6.000K
YoY Change 2383.33% -166.67%
% of Operating Profit
Other Income/Expense, Net $370.0K -$772.0K
YoY Change -147.93%
Pretax Income -$23.93M -$12.28M
YoY Change 94.95% 185.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.93M -$12.28M
YoY Change 94.95% 185.36%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$513.6K -$275.9K
COMMON SHARES
Basic Shares Outstanding 46.63M
Diluted Shares Outstanding 46.60M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $317.2M $168.4M
YoY Change 88.3%
Cash & Equivalents $138.3M $168.4M
Short-Term Investments $178.9M
Other Short-Term Assets $3.203M $3.271M
YoY Change -2.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $320.4M $171.7M
YoY Change 86.58%
LONG-TERM ASSETS
Property, Plant & Equipment $13.40M $7.732M
YoY Change 73.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.333M $1.164M
YoY Change 358.16%
Total Long-Term Assets $25.64M $8.896M
YoY Change 188.21%
TOTAL ASSETS
Total Short-Term Assets $320.4M $171.7M
Total Long-Term Assets $25.64M $8.896M
Total Assets $346.0M $180.6M
YoY Change 91.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.511M $7.326M
YoY Change -38.42%
Accrued Expenses $7.979M $1.765M
YoY Change 352.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.49M $9.091M
YoY Change 37.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.640M $956.0K
YoY Change 699.16%
Total Long-Term Liabilities $7.640M $956.0K
YoY Change 699.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.49M $9.091M
Total Long-Term Liabilities $7.640M $956.0K
Total Liabilities $20.13M $10.05M
YoY Change 100.36%
SHAREHOLDERS EQUITY
Retained Earnings -$146.0M
YoY Change
Common Stock $474.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $325.9M -$60.62M
YoY Change
Total Liabilities & Shareholders Equity $346.0M $180.6M
YoY Change 91.58%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$23.93M -$12.28M
YoY Change 94.95% 185.36%
Depreciation, Depletion And Amortization $800.0K $300.0K
YoY Change 166.67% 322.54%
Cash From Operating Activities -$27.40M -$13.82M
YoY Change 98.36% 309.21%
INVESTING ACTIVITIES
Capital Expenditures $1.687M $2.217M
YoY Change -23.91% -17153.85%
Acquisitions
YoY Change
Other Investing Activities -$178.8M
YoY Change
Cash From Investing Activities -$180.5M -$2.217M
YoY Change 8042.53% 16953.85%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 153.0K 142.8M
YoY Change -99.89%
NET CHANGE
Cash From Operating Activities -27.40M -13.82M
Cash From Investing Activities -180.5M -2.217M
Cash From Financing Activities 153.0K 142.8M
Net Change In Cash -207.8M 126.7M
YoY Change -263.94% -3839.66%
FREE CASH FLOW
Cash From Operating Activities -$27.40M -$13.82M
Capital Expenditures $1.687M $2.217M
Free Cash Flow -$29.09M -$16.03M
YoY Change 81.46% 376.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001826457
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40522
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
645 Summer Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
949-2643
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
GLUE
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 glue Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
6910000
CY2021Q4 glue Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
0
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5333000
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46668422
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138305000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
346071000
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
178858000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3203000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2595000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
320366000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
348666000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13396000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5338000
CY2022Q1 us-gaap Assets
Assets
346005000
CY2021Q4 us-gaap Assets
Assets
366329000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4511000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6558000
CY2021Q4 glue Current Portion Of Operating Lease Liability
CurrentPortionOfOperatingLeaseLiability
0
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12490000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16638000
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
6455000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10080000
CY2022Q1 glue Current Portion Of Operating Lease Liability
CurrentPortionOfOperatingLeaseLiability
1524000
CY2022Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2183000
CY2021Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2176000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5457000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q1 us-gaap Liabilities
Liabilities
20130000
CY2021Q4 us-gaap Liabilities
Liabilities
18814000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46854535
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46630711
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46794295
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46535966
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473970000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471566000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2133000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2021000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145967000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122035000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
325875000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
346005000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
366329000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17915000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9273000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6387000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2231000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
24302000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
11504000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24302000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11504000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
149000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
96000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
182000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
125000
CY2021Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2022Q1 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
CY2021Q1 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2022Q1 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
34000
CY2021Q1 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
136000
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
146000
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24044000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12140000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.51
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
7.18
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46595782
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1709227
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-48728000
CY2021Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
136000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-60616000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
34000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2251000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
146000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
325875000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-23932000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-12276000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2251000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
252000
CY2022Q1 us-gaap Depreciation
Depreciation
753000
CY2021Q1 us-gaap Depreciation
Depreciation
274000
CY2022Q1 glue Noncash Lease Expense
NoncashLeaseExpense
379000
CY2022Q1 glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-45000
CY2021Q1 glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
0
CY2022Q1 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
CY2021Q1 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
125000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
608000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1381000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2184000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-906000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3559000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-738000
CY2022Q1 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-41000
CY2021Q1 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
0
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-375000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27404000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13815000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1687000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2217000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
125000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
178958000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180520000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2217000
CY2022Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
143000000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
231000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
153000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
142769000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-207771000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
126737000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143638000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169600000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138305000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168436000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
5333000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1164000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143638000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169600000
CY2022Q1 glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
0
CY2021Q1 glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
20640000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
794000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1166000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-3.5305
CY2021Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
31068102
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146000000.0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23900000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
317200000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
5300000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7300000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7400000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306310000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
179004000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
151000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
178858000
CY2022Q1 glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
13
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
80300000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16675000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15028000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3279000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2703000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13396000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2022Q1 us-gaap Depreciation
Depreciation
800000
CY2021Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
502000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
118000
CY2022Q1 us-gaap Lease Cost
LeaseCost
620000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7289000
CY2022Q1 glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
347000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2021Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
63327
CY2021Q4 glue Lease Commencement Date
LeaseCommencementDate
2022-04-01
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P128M
CY2021Q4 us-gaap Payments For Rent
PaymentsForRent
95.00
CY2021Q4 glue Increase In Annual Base Rent Percentage
IncreaseInAnnualBaseRentPercentage
0.03
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
500000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6200000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6400000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
6600000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6800000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
44400000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3160000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
8353000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
8583000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8820000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
7298000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
44360000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
80574000
CY2022Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company’s board of directors approved a one-for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company’s preferred stock effective as of June 17, 2021
CY2021Q2 glue Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46854535
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46630711
CY2022Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2022Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7328755
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5821842
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5563513
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70045000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1671875
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.41
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60240
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.53
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
70217
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.25
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7104931
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.28
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40521000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
909028
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.82
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8756000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1709227
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
500000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2251000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.51
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
7.18
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46595782
CY2022Q1 us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
200000
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5400000

Files In Submission

Name View Source Status
0000950170-22-009324-index-headers.html Edgar Link pending
0000950170-22-009324-index.html Edgar Link pending
0000950170-22-009324.txt Edgar Link pending
0000950170-22-009324-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glue-20220331.htm Edgar Link pending
glue-20220331.xsd Edgar Link pending
glue-20220331_cal.xml Edgar Link unprocessable
glue-20220331_def.xml Edgar Link unprocessable
glue-20220331_htm.xml Edgar Link completed
glue-20220331_lab.xml Edgar Link unprocessable
glue-20220331_pre.xml Edgar Link unprocessable
glue-ex10_2.htm Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex31_2.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending